Biotech: Page 35
-
Permission granted by Novartis
IFM, an unorthodox biotech startup, scores third buyout with Novartis deal
With a decision by the Swiss pharma to acquire another one of its subsidiaries, IFM Therapeutics has now sold three spin-offs for a total of $700 million upfront and the potential for billions more in future payments.
By Kristin Jensen • March 13, 2024 -
Getty Images
Allogene taps Arbor in pursuit of ‘off-the-shelf’ CAR-T therapies for autoimmune disease
The partnership is designed to help the company stand out in what’s quickly become one of the industry’s hottest areas of drug research.
By Ben Fidler • March 12, 2024 -
Explore the Trendline➔
Spencer Platt via Getty Images
TrendlineEmerging biotech
New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.
By BioPharma Dive staff -
Permission granted by Amylyx Pharmaceuticals
ALS drug developmentAfter surprise trial failure, ALS doctors brace for one less treatment option
Physicians have been preparing for tough conversations with patients on Amylyx's drug since negative confirmatory trial results in March.
By Jacob Bell • Updated April 4, 2024 -
Getty Images
Boehringer, Sosei Heptares team up in schizophrenia drug deal
Sosei Heptares could receive more than 700 million euros in a deal to develop medicines aimed at the protein GPR52, an emerging drug target in multiple neurological diseases.
By Delilah Alvarado • March 11, 2024 -
Permission granted by Amylyx Pharmaceuticals
Q&AAmylyx CEOs look for a path forward following major setback
Justin Klee and Joshua Cohen spoke to BioPharma Dive about the next steps for their company, which is considering pulling its only product from market after the drug failed a confirmatory study in ALS.
By Jacob Bell • March 11, 2024 -
Getty Images
Biotech stock fundings headed for best quarter in 3 years, Jefferies says
Publicly traded companies raised nearly $10 billion in follow-on stock offerings in January and February, a financing surge that’s driving a “sector recovery,” the investment bank said.
By Ben Fidler • March 11, 2024 -
Getty Images
Sponsored by PurpleLabCan using SDoH data help identify patient populations who could benefit from weight loss drugs?
SDoH data can help companies understand the footprint of weight loss medications in the market and their impact across populations.
March 11, 2024 -
Permission granted by Amylyx Pharmaceuticals
Amylyx ALS drug fails crucial study, putting company’s future in doubt
The results have led Amylyx to pause promotion of Relyvrio and potentially pull it from the market in the coming weeks, a major blow to the company and ALS patients.
By Jacob Bell • Updated March 8, 2024 -
Michael M. Santiago via Getty Images
Boundless Bio, a Bayer-backed cancer biotech, seeks an IPO
The startup, which has raised nearly $254 million privately, is in early testing with drugs designed to target particularly tough-to-treat tumors.
By Gwendolyn Wu • March 7, 2024 -
Getty Images
European VC Invivo readies its latest fund to back new biotechs
The Barcelona-based firm, which is targeting about 100 million euros for the new fund, is eyeing investments in AI, synthetic biology, and cell and gene therapy.
By Gwendolyn Wu • March 6, 2024 -
Getty Images
Alumis, taking aim at Bristol Myers, pulls in $259M for TYK2 drug work
The startup, one of a number of young biotechs coming after Bristol Myers’ Sotyktu, will use the cash to fund a late-stage trial in plaque psoriasis.
By Delilah Alvarado • March 6, 2024 -
Permission granted by Sionna Therapeutics
Sionna raises another $182M to challenge Vertex in cystic fibrosis
Incubated by RA Capital and backed by a wide array of investors, the startup is developing drugs that work differently than Vertex’s market-leading medicines.
By Gwendolyn Wu • March 6, 2024 -
Permission granted by Nasdaq, Inc.
Biotech IPOs heated up to start 2024. Will the surge last?
Following the sector’s best IPO start in three years, BioPharma Dive spoke with industry insiders about what they expect to see in the months ahead.
By Gwendolyn Wu , Ben Fidler • March 5, 2024 -
Getty Images
Nocion, chasing GSK, pulls in $62M for chronic cough drug
Nocion will use the cash to start a mid-stage trial testing its medicine, a potential rival to a drug GSK acquired last year in a $2 billion deal.
By Gwendolyn Wu • March 4, 2024 -
Getty Images
Bayer pays $310M to buy into BridgeBio heart drug
The deal gives the German pharma partial rights to a closely watched medicine for transthyretin amyloidosis cardiomyopathy that analysts expect to become a multibillion-dollar product.
By Ben Fidler • March 4, 2024 -
Permission granted by QIAGEN
Sponsored by QIAGENUsing knowledge graphs to drive drug discovery
How are knowledge graphs changing the path of drug discovery?
March 4, 2024 -
Permission granted by FogPharma
FogPharma pulls in $145M to support cancer drug research
The cash will be used to advance development of FOG-001, the company’s lead drug that’s now being tested in an early-stage trial for solid tumors.
By Gwendolyn Wu • March 1, 2024 -
Getty Images
Gritstone to lay off 40% of workforce after costly study delay
The restructuring comes ahead of a key study readout for Gritstone, which, like Moderna, is developing a type of personalized cancer vaccine.
By Ben Fidler • March 1, 2024 -
Courtesy of Cure Ventures
Cure Ventures backs a cell therapy startup targeting Parkinson’s
The startup, Kenai Therapeutics, has raised $82 million and will be chaired by Jeff Jonas, a new Cure partner and former CEO of Sage Therapeutics.
By Jacob Bell • Feb. 29, 2024 -
Getty Images
With BlossomHill, former Turning Point execs take aim at cancer, autoimmune disease
Less than two years after Bristol Myers bought Turning Point for $4.1 billion, Jean Cui and Peter Li have built a new startup that’s brought in more than $170 million in funding.
By Ned Pagliarulo • Feb. 29, 2024 -
Permission granted by Gilead Sciences
Abingworth invests in Trodelvy development in deal with Gilead
One of the investment firm’s startups will work with Gilead to expand the cancer drug’s label under the unusual arrangement, with Abingworth receiving payment if successful.
By Kristin Jensen • Feb. 29, 2024 -
Getty Images
Women’s health company Obseva to wind down, lay off staff
The company is still attempting to “monetize” its most advanced drug, a treatment to aid pregnancy via in vitro fertilization.
By Delilah Alvarado • Feb. 28, 2024 -
Viatris pays $350M to gain two drugs from Idorsia
The deal gives Viatris access to a treatment for heart attacks as well as a drug for lupus, both of which are currently in Phase 3 testing.
By Kristin Jensen • Feb. 28, 2024 -
Courtesy of Ginkgo Bioworks
Ginkgo adds gene editing tools in buyout of Feng Zhang-founded startup
The acquisition of Proof Diagnostics, which was formed to develop a COVID-19 test, gives Ginkgo a library of novel enzymes for making genetic medicines.
By Gwendolyn Wu • Feb. 28, 2024 -
Permission granted by Lindus Health
Can a Moderna co-founder change the CRO game?
Well-known scientist and biotech entrepreneur Robert Langer is helping Lindus Health address longstanding challenges in contract drug research.
By Michael Gibney • Feb. 28, 2024
Previous
